Skip to content

X - PHARMA

Active Public limited companyfounded 1993active for 33 yearsPlace de Petit-Rechain 21, 4800 VerviersKBO/BCE: BE 0449.256.092

Lifetime

20 annual accounts with figures on one time axis, 32 filings since 1994
peak of €15,883 in 2019
€15,417▼ 0.4%
lowest -€718 in 2012
€9,962▼ 43.3%
peak of €148,387 in 2025
€148,387▲ 7.2%
€1,763▼ 62.8%
Board8 names since 2018
8 directors and 7 others
Documentsfilings and deeds
06-05-202686 days before the deadline
2025micro format
Result from €17,556 to €9,962Debts from €4,739 to €1,763

Key points

from the 2025 annual accounts

Equity

€148,387 ▲ 7.2%

X - PHARMA has made a profit without a break since 2013.

Liquidity

59.22 was 20.55 in 2024

Short-term debts fell from €4,739 to €1,763.

Filings

32 annual accounts since 1994
AprilJune31 JulyOctober200020102020

The last five annual accounts were filed 31 to 86 days before the end of the period.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 31,386 companies had the same profile as X - PHARMA has now. Each dot stands for 79 companies, two years later.

93.4%
were still trading
6.0%
stopped another way
0.5%
went bankrupt
  • Micro
  • 20 years or older
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more

Another 0.1% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,760 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 31,386 companies, not a prediction for X - PHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Chair
Managing director
Director, since 12-12-2023
Director, since 12-12-2023
Director, since 12-12-2023
Director, since 12-12-2023
and 2 othersBoard & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0449256092
2 directors appointed, 4 reappointments , , and reappointed · (chair of the board) and (day-to-day manager) appointed · “L’exploitation, l’achat, la vente, la location d’officines pharmaceutiques; Apporter son concours aux…” (deed in French) · General meeting of 12-12-2023 · Gazette deed
Resignations & appointments Board composition: (managing director) · Board composition: (director) · Board composition: (director) · General meeting of 06-06-2018 · Gazette deed
4 directors reappointed , , and · General meeting of 23-04-2018 · Gazette deed
All 46 events

Comparable companies

same main activity, similar in size and age
Company
X - PHARMA Verviers €150,150 €15,417 98.8% -
Apotheek Els De Smedt Beveren-Kruibeke-Zwijndrecht €157,911 €12,944 2.9% -
MONT ROYAL Brussels €126,135 €18,242 61.2% -
APOTHEEK D'HONDT PASCAL Lokeren €177,633 €17,317 90.1% 0
MEDISAME Stabroek €184,789 €19,805 -37.6% -
PHARMACIE ANS SENTERRE Ans €132,785 €25,091 32.0% -
GENAPHAR Brussels €147,330 €18,365 66.3% -

These companies have the same main activity as X - PHARMA: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €126,000 and €185,000, founded between 1976 and 2001.

Official details

Source: KBO
Status
Active since 20-01-1993Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730
Establishment unit
2.061.244.1594652 Herve, since 10-03-1993
Financial year end
31 December
Peppol
Reachable since 15-09-2025
Company details

Annual accounts 2025

≈ €170,000estimated
€150,150▲ 4.9%
Filing
Filed on 06-05-2026, 86 days before the end of the filing period
Financials

Insights on X - PHARMA

X - PHARMA files the micro format. That format states no turnover. The gross margin rose from €1,381 in 2006 to €15,417 in 2025.

In December 2023, the Official Gazette published the appointment of as managing director.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about X - PHARMA

What is the company number of X - PHARMA?
The company number of X - PHARMA is 0449.256.092. The VAT number is the same number with BE in front: BE 0449.256.092.
Where is X - PHARMA based?
The registered office is at Place de Petit-Rechain 21, 4800 Verviers.Company details
What does X - PHARMA do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of X - PHARMA?
X - PHARMA is a public limited company (NV).
When was X - PHARMA founded?
X - PHARMA was founded on 20-01-1993.
Is X - PHARMA still active?
Yes, X - PHARMA is an active enterprise in the KBO register.
What is the turnover of X - PHARMA?
The turnover in financial year 2025 is ≈ €170,000. This figure is estimated from the gross margin of €15,417 and 138 comparable companies (NACE 477). It probably lies between €61,000 and €350,000. It is a rough estimate.Financials
Is X - PHARMA profitable?
In financial year 2025, X - PHARMA made a profit of €9,962.
Where can I find the annual accounts of X - PHARMA?
X - PHARMA filed 32 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of X - PHARMA due?
X - PHARMA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.